CDP2 Inhibitors
Chemical inhibitors of CDP2 function primarily through the interruption of signaling pathways and phosphorylation events that are crucial for the protein's activity. Alsterpaullone and Indirubin-3'-monoxime can inhibit cyclin-dependent kinases, which are integral to cell cycle regulation. By halting these kinases, the phosphorylation and, consequently, the activity of CDP2 can be disrupted. Similarly, SP600125 targets the c-Jun N-terminal kinase (JNK), a kinase that can modify the activity of various transcription factors, including CDP2. The inhibition of JNK can lead to a decrease in CDP2 activity by hindering phosphorylation processes that CDP2 may depend on. 5-Iodotubercidin raises intracellular adenosine levels, influencing kinase activity and potentially reducing the phosphorylation of proteins that interact with CDP2, leading to its functional inhibition.
Continuing with this theme, Ro-31-8220 and H-89 exert their effects by inhibiting protein kinase C (PKC) and protein kinase A (PKA), respectively. These kinases are responsible for the phosphorylation of a wide range of proteins, including those involved in regulating transcription factors like CDP2. Consequently, their inhibition can result in reduced CDP2 function. U0126 and PD98059, both MEK inhibitors, prevent the activation of the ERK1/2 MAP kinases, which are known to regulate transcription factors and could thus inhibit CDP2. Similarly, the ROCK inhibitor Y-27632 can affect the cytoskeletal dynamics that are connected to the regulation of transcription factors, potentially inhibiting CDP2 activity. SB203580, a p38 MAP kinase inhibitor, disrupts the phosphorylation of transcription factors that may interact with or control the activity of CDP2. LY294002, a PI3K inhibitor, impedes the PI3K/AKT signaling pathway, which is pivotal for the regulation of various proteins, including transcription factors, thereby affecting CDP2 function. Lastly, Thapsigargin, by inhibiting the SERCA pump and increasing cytosolic calcium levels, can alter the activities of calcium-dependent kinases and phosphatases, which may inhibit the function of CDP2 by modifying the phosphorylation status of associated proteins.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs) which are involved in the cell cycle regulation. Since CDP2 is a transcription factor that may be regulated by the cell cycle, inhibiting CDKs can lead to the suppression of CDP2 activity by preventing its required phosphorylation or changing its expression pattern. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
This molecule is an inhibitor of CDKs and GSK-3β. GSK-3β inhibition can lead to altered transcription factor dynamics, and since transcription factors like CDP2 can be regulated by phosphorylation, this may result in the functional inhibition of CDP2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can influence transcription factor activities. By inhibiting JNK, this compound could prevent the phosphorylation of transcription factors related to the pathways that CDP2 is involved in, resulting in decreased CDP2 activity. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $150.00 $455.00 | 20 | |
As an adenosine kinase inhibitor, 5-Iodotubercidin raises intracellular adenosine levels which can modulate kinase activity. This modulation may decrease the phosphorylation of transcription factors and proteins associated with CDP2, thereby inhibiting CDP2 function. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $90.00 $240.00 | 17 | |
Ro-31-8220 is a potent PKC inhibitor that could inhibit the phosphorylation of transcription factors and proteins that interact with CDP2, leading to a functional inhibition of CDP2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor, which prevents the activation of ERK1/2 MAP kinases. The ERK pathway is known to regulate various transcription factors; thus, inhibiting MEK could inhibit CDP2 function by preventing the necessary phosphorylation events or protein interactions. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, and by inhibiting ROCK it can affect actin cytoskeleton dynamics. Since transcription factors such as CDP2 can be regulated by cytoskeletal interactions, this could inhibit the function of CDP2 by preventing its proper localization or interaction with other proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a p38 MAP kinase inhibitor. Inhibition of p38 MAP kinase can disrupt the phosphorylation of downstream transcription factors, potentially inhibiting CDP2 by preventing activation of pathways it is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which would prevent the activation of AKT. Since AKT can regulate numerous transcription factors and proteins through phosphorylation, inhibiting PI3K/AKT signaling could lead to an inhibition of CDP2 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Inhibition of this pathway could result in the functional inhibition of CDP2 by altering the phosphorylation and activity of transcription factors and proteins associated with the pathways CDP2 operates within. | ||||||